Paget's bone disease treated with diphosphonate and calcitonin

Area of Science:

• Endocrinology
• Bone Metabolism
• Pharmacology

Background:

• Paget's disease of bone is characterized by abnormal bone remodeling.
• Current treatments for biochemically active Paget's disease include bisphosphonates and calcitonin.
• Optimizing treatment efficacy while minimizing side effects is crucial.

Purpose of the Study:

• To evaluate the efficacy of a combination therapy for Paget's disease.
• To compare the effects of low-dose disodium ethane-1-hydroxy-1,1-diphosphonate (E.H.D.P.) plus calcitonin with higher doses of calcitonin alone.
• To assess the impact on biochemical markers and bone histology.

Main Methods:

• Patients with active Paget's disease received low-dose E.H.D.P. and synthetic human calcitonin.
• Biochemical markers of bone turnover were monitored.
• Bone biopsies were performed to assess histological changes, including osteoblast and osteoclast activity and mineralization.

Main Results:

• The combination therapy demonstrated greater and more consistent biochemical improvements than higher doses of calcitonin alone.
• Bone biopsies revealed a decrease or disappearance of abnormal osteoblasts and osteoclasts in pagetic lesions.
• The addition of calcitonin to E.H.D.P. effectively prevented the development of mineralization defects.

Conclusions:

• Combination therapy with low-dose E.H.D.P. and calcitonin is a highly effective treatment for Paget's disease.
• This regimen offers superior biochemical and histological benefits compared to calcitonin monotherapy.
• The combination therapy addresses both abnormal bone turnover and mineralization issues in Paget's disease.